Cardiovascular Advances in Research and Opportunities Legacy Act

Bill: 117-s-1133
Sponsor: full_name: Sen. McConnell, Mitch [R-KY]
Introduced: 2021-04-15
Policy area: Health
Subjects: Advanced technology and technological innovations

Cardiovascular and respiratory health

Government information and archives

Health information and medical records

Health programs administration and funding

Health promotion and preventive care

Health technology, devices, supplies

Medical research

Medical tests and diagnostic methods

Photography and imaging

Research administration and funding
Latest action: action_date: 2021-04-15
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1984; text: CR S1985)

Summaries:
action_date: 2021-04-15
action_desc: Introduced in Senate
text: <p><b>Cardiovascular Advances in Research and Opportunities Legacy Act</b></p> <p>This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.</p> <p>The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.</p> <p>The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.</p>

tv_txt: II 117th CONGRESS 1st Session S. 1133 IN THE SENATE OF THE UNITED STATES April 15, 2021 Mr. McConnell (for himself and Ms. Sinema ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program to support or conduct research on valvular heart disease, and for other purposes.

1. Short title This Act may be cited as the Cardiovascular Advances in Research and Opportunities Legacy Act . 2. Grants for valvular heart disease research Subpart 2 of part C of title IV of the Public Health Service Act ( 42 U.S.C. 285b et seq.) is amended by inserting after section 424C the following: 424D. Grants for valvular heart disease research (a) In general The Director of the National Institutes of Health, in consultation with the Director of the Institute, shall support or conduct research regarding valvular heart disease. (b) Support guidelines The distribution of funding authorized in subsection (a) may be used to pursue any of the following outcomes: (1) Using precision medicine and advanced technological imaging to generate data on individuals with valvular heart disease. (2) Identifying and developing a cohort of individuals with valvular heart disease and available data. (3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease. (4) Other outcomes needed to acquire necessary data on valvular heart disease. (c) Mitral valve prolapse workshop Not later than one year after the date of enactment of this section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop prescriptive guidelines for treatment of individuals with mitral valve prolapse. (d) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated $20,000,000 for each of fiscal years 2022 through 2026. . 3. Programs of centers for disease control and prevention Part J of title III of the Public Health Service Act ( 42 U.S.C. 280b et seq.) is amended by inserting after section 393D the following section: 393E. Prevention of sudden cardiac death as a result of valvular heart disease (a) In general The Secretary, acting through the Director of the Centers for Disease Control and Prevention, may carry out projects to increase education, awareness, or diagnosis of valvular heart disease and to reduce the incidence of sudden cardiac death caused by valvular heart disease. Such projects may be carried out by the Secretary directly or through awards of grants or contracts to public or nonprofit private entities. The Secretary may directly (or through such awards) provide technical assistance with respect to the planning, development, and operation of such projects. (b) Certain activities Projects carried out under subsection (a) may include— (1) the implementation of public information and education programs for— (A) the prevention of sudden cardiac death from valvular heart disease; (B) broadening the awareness of the public concerning the risk factors for, the symptoms of, and the public health consequences of, valvular heart disease; and (C) increasing screening, detection, and diagnosis of valvular heart disease; and (2) surveillance of out-of-hospital cardiac arrests to improve patient outcomes. (c) Grant prioritization The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by valvular heart disease. (d) Coordination of activities The Secretary shall ensure that activities under this section are coordinated, as appropriate, with other agencies of the Public Health Service that carry out activities regarding valvular heart disease. (e) Best practices The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall— (1) collect and analyze the findings of research conducted with respect to valvular heart disease; and (2) taking into account such findings, publish on the website of the Centers for Disease Control and Prevention best practices for physicians and other health care providers who provide care to individuals with valvular heart disease. (f) Authorization of appropriations For the purpose of carrying out this section, there is authorized to be appropriated such sums as may be necessary for each of fiscal years 2022 through 2026. .